Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Ongoing Exposure of U.K. Infants to Vaccine Serotype Pneumococci.

Slack M, Vyse A, Madhava H, Reinert RR, Ellsbury G, Czudek C, Gessner B.

Pediatr Infect Dis J. 2019 Apr;38(4):444. doi: 10.1097/INF.0000000000002184. No abstract available.

PMID:
30882750
2.

Burden of Invasive Pneumococcal Disease.

Slack M, Vyse A, Madhava H, Ellsbury G, Czudek C, Reinert RR, Gessner B.

Clin Infect Dis. 2019 Sep 27;69(8):1465-1466. doi: 10.1093/cid/ciz190. No abstract available.

PMID:
30843037
3.

Response to Mungall et al. letter to the editor on Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Gessner B, Jodar L.

Expert Rev Vaccines. 2018 Aug;17(8):669-671. doi: 10.1080/14760584.2018.1506207. Epub 2018 Aug 2. No abstract available.

PMID:
30071169
4.

Streptococcus pneumoniae serotype 19A: worldwide epidemiology.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L.

Expert Rev Vaccines. 2017 Oct;16(10):1007-1027. doi: 10.1080/14760584.2017.1362339. Epub 2017 Aug 28. Review.

PMID:
28783380
5.

Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies.

Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, Reinert RR, Schmitt HJ, Trucchi C, Vestraeten T, Ansaldi F.

PLoS One. 2017 May 23;12(5):e0177985. doi: 10.1371/journal.pone.0177985. eCollection 2017. Review.

6.

Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2015 Oct;305(7):776-83. doi: 10.1016/j.ijmm.2015.08.031. Epub 2015 Aug 22.

PMID:
26324014
7.

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ.

Ann Clin Microbiol Antimicrob. 2015 May 10;14:27. doi: 10.1186/s12941-015-0085-1.

8.

Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany.

Imöhl M, Möller J, Reinert RR, Perniciaro S, van der Linden M, Aktas O.

BMC Infect Dis. 2015 Feb 14;15:61. doi: 10.1186/s12879-015-0787-1.

9.

Erratum to: Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T.

Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):415-6. doi: 10.1007/s10096-014-2258-9. No abstract available.

10.

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T.

Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):19-31. doi: 10.1007/s10096-014-2208-6. Epub 2014 Aug 23. Review. Erratum in: Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):415-6.

11.

Penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013).

Imöhl M, Reinert RR, Tulkens PM, van der Linden M.

Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2035-40. doi: 10.1007/s10096-014-2174-z. Epub 2014 Jun 15.

PMID:
24930041
12.

Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.

Tatochenko V, Sidorenko S, Namazova-Baranova L, Mayanskiy N, Kulichenko T, Baranov A, Lobzin Y, Kharit S, Kozlov R, Andreeva I, Muravjev A, Chagaryan A, Koroleva I, Beloshitskiy G, Mironov K, Degtyareva E, Reinert RR.

Expert Rev Vaccines. 2014 Feb;13(2):257-64. doi: 10.1586/14760584.2013.871205. Epub 2013 Dec 18. Review.

PMID:
24350587
13.

Epidemiology of Streptococcus pneumoniae serogroup 6 isolates from IPD in children and adults in Germany.

van der Linden M, Winkel N, Küntzel S, Farkas A, Perniciaro SR, Reinert RR, Imöhl M.

PLoS One. 2013 Apr 9;8(4):e60848. doi: 10.1371/journal.pone.0060848. Print 2013.

14.

Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children.

van der Linden M, Reinert RR, Kern WV, Imöhl M.

BMC Infect Dis. 2013 Feb 5;13:70. doi: 10.1186/1471-2334-13-70.

15.

Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression.

Uciechowski P, Imhoff H, Lange C, Meyer CG, Browne EN, Kirsten DK, Schröder AK, Schaaf B, Al-Lahham A, Reinert RR, Reiling N, Haase H, Hatzmann A, Fleischer D, Heussen N, Kleines M, Rink L.

J Leukoc Biol. 2011 Aug;90(2):377-88. doi: 10.1189/jlb.0409233. Epub 2011 Jun 3.

PMID:
21642391
16.

mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany.

Bley C, van der Linden M, Reinert RR.

Int J Antimicrob Agents. 2011 May;37(5):425-31. doi: 10.1016/j.ijantimicag.2011.01.019. Epub 2011 Mar 21.

PMID:
21419605
17.

Invasive group A streptococcal disease and association with varicella in Germany, 1996-2009.

Imöhl M, van der Linden M, Reinert RR, Ritter K.

FEMS Immunol Med Microbiol. 2011 Jun;62(1):101-9. doi: 10.1111/j.1574-695X.2011.00788.x. Epub 2011 Mar 2.

18.

Global prevailing and emerging pediatric pneumococcal serotypes.

McIntosh ED, Reinert RR.

Expert Rev Vaccines. 2011 Jan;10(1):109-29. doi: 10.1586/erv.10.145. Review.

PMID:
21162625
19.

Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008.

Imöhl M, Reinert RR, Mutscher C, van der Linden M.

BMC Microbiol. 2010 Nov 25;10:299. doi: 10.1186/1471-2180-10-299.

20.

Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008).

Imöhl M, Reinert RR, van der Linden M.

Int J Microbiol. 2010;2010:874189. doi: 10.1155/2010/874189. Epub 2010 Jun 30.

21.

Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method.

Rückinger S, van der Linden M, Reinert RR, von Kries R.

Vaccine. 2010 Jul 12;28(31):5012-6. doi: 10.1016/j.vaccine.2010.05.021. Epub 2010 May 21.

PMID:
20546832
22.

Superantigen genes are more important than the emm type for the invasiveness of group A Streptococcus infection.

Lintges M, van der Linden M, Hilgers RD, Arlt S, Al-Lahham A, Reinert RR, Plücken S, Rink L.

J Infect Dis. 2010 Jul 1;202(1):20-8. doi: 10.1086/653082.

PMID:
20497047
23.

Serotype distribution of invasive pneumococcal disease during the first 60 days of life.

Imöhl M, van der Linden M, Mutscher C, Reinert RR.

Vaccine. 2010 Jul 5;28(30):4758-62. doi: 10.1016/j.vaccine.2010.04.097. Epub 2010 May 14.

PMID:
20472027
24.

Serotype distribution in pneumococcal acute otitis media with ruptured tympanic membrane or sepsis in Germany.

van der Linden M, Reinert RR.

Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):749-54. doi: 10.1007/s10096-010-0945-8. Epub 2010 Apr 30. Review. Erratum in: Eur J Clin Microbiol Infect Dis. 2010 Aug;29(8):1047.

PMID:
20432051
25.

Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.

Reinert RR, Paradiso P, Fritzell B.

Expert Rev Vaccines. 2010 Mar;9(3):229-36. doi: 10.1586/erv.10.6. Review. No abstract available.

PMID:
20218848
26.

Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007.

Imöhl M, Reinert RR, Ocklenburg C, van der Linden M.

FEMS Immunol Med Microbiol. 2010 Apr;58(3):389-96. doi: 10.1111/j.1574-695X.2010.00652.x. Epub 2010 Jan 19.

27.

Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease.

Imöhl M, Reinert RR, Ocklenburg C, van der Linden M.

J Clin Microbiol. 2010 Apr;48(4):1291-6. doi: 10.1128/JCM.01937-09. Epub 2010 Jan 27.

28.

Risk factor analysis for pneumococcal meningitis in adults with invasive pneumococcal infection.

Burckhardt I, Burckhardt F, VAN DER Linden M, Heeg C, Reinert RR.

Epidemiol Infect. 2010 Sep;138(9):1353-8. doi: 10.1017/S0950268809991683. Epub 2010 Jan 22.

PMID:
20092671
29.

Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Jun;300(5):324-30. doi: 10.1016/j.ijmm.2009.11.004. Epub 2010 Jan 13.

PMID:
20071233
30.

Molecular characterization of pneumococcal isolates from pets and laboratory animals.

van der Linden M, Al-Lahham A, Nicklas W, Reinert RR.

PLoS One. 2009 Dec 14;4(12):e8286. doi: 10.1371/journal.pone.0008286.

31.

Effects of preincubation temperature on the detection of fastidious organisms in delayed-entry samples in the BacT/ALERT 3D blood culture system.

Wilms MC, Stanzel S, Reinert RR, Burckhardt I.

J Microbiol Methods. 2009 Nov;79(2):194-8. doi: 10.1016/j.mimet.2009.08.015. Epub 2009 Sep 4.

PMID:
19733598
33.
34.

Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Apr;300(4):237-47. doi: 10.1016/j.ijmm.2009.05.005. Epub 2009 Jul 14.

PMID:
19604721
35.

Distribution of emm types among group A streptococcal isolates from Serbia.

Mijac V, Ranin L, Marković M, Heeg C, Reinert RR, Opavski N.

Clin Microbiol Infect. 2010 Mar;16(3):295-8. doi: 10.1111/j.1469-0691.2009.02823.x. Epub 2009 Jun 6.

36.

New penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effects on susceptibility categorisation in Germany (1992-2008).

Imöhl M, Reinert RR, van der Linden M.

Int J Antimicrob Agents. 2009 Sep;34(3):271-3. doi: 10.1016/j.ijantimicag.2009.03.022. Epub 2009 May 5.

PMID:
19419844
37.

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.

Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A.

Vaccine. 2009 Jun 24;27(31):4136-41. doi: 10.1016/j.vaccine.2009.04.057. Epub 2009 May 9.

PMID:
19406190
38.

The antimicrobial resistance profile of Streptococcus pneumoniae.

Reinert RR.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:7-11. doi: 10.1111/j.1469-0691.2009.02724.x. Review.

39.

The public health ramifications of pneumococcal resistance.

Reinert RR.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:1-3. doi: 10.1111/j.1469-0691.2009.02722.x. No abstract available.

40.

Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.

Rückinger S, von Kries R, Reinert RR, van der Linden M, Siedler A.

Vaccine. 2008 Jul 29;26(32):3984-6. doi: 10.1016/j.vaccine.2008.04.031. Epub 2008 May 5.

PMID:
18495301
41.

Epidemiology of severe Streptococcus pyogenes disease in Europe.

Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalén C; Strep-EURO Study Group, Jasir A.

J Clin Microbiol. 2008 Jul;46(7):2359-67. doi: 10.1128/JCM.00422-08. Epub 2008 May 7.

42.

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.

Claes C, Reinert RR, von der Schulenburg JM.

Eur J Health Econ. 2009 Feb;10(1):25-38. doi: 10.1007/s10198-008-0098-1. Epub 2008 Apr 1.

PMID:
18379830
43.

Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia.

Reinert RR, Filimonova OY, Al-Lahham A, Grudinina SA, Ilina EN, Weigel LM, Sidorenko SV.

Antimicrob Agents Chemother. 2008 Jun;52(6):2260-2. doi: 10.1128/AAC.01270-07. Epub 2008 Mar 31.

44.

Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).

de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galán JC, Baquero F, Reinert RR, Cantón R.

Antimicrob Agents Chemother. 2008 Jun;52(6):1964-9. doi: 10.1128/AAC.01487-07. Epub 2008 Mar 24.

45.

Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE.

Drugs. 2007;67(16):2355-82. Review.

PMID:
17983256
46.

Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.

Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.

J Antimicrob Chemother. 2007 Nov;60(5):1018-29. Epub 2007 Sep 13.

PMID:
17855724
47.

Epidemiology of invasive Streptococcus pyogenes infections in Germany, 1996-2002: results from a voluntary laboratory surveillance system.

Wahl RU, Lütticken R, Stanzel S, van der Linden M, Reinert RR.

Clin Microbiol Infect. 2007 Dec;13(12):1173-8. Epub 2007 Sep 10.

48.

Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.

Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS.

Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):531-40.

PMID:
17570001
49.

Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia.

Schaaf B, Kruse J, Rupp J, Reinert RR, Droemann D, Zabel P, Ewig S, Dalhoff K.

Eur Respir J. 2007 Sep;30(3):517-24. Epub 2007 May 30.

50.

A new closed-tube multiplex real-time PCR to detect eleven superantigens of Streptococcus pyogenes identifies a strain without superantigen activity.

Lintges M, Arlt S, Uciechowski P, Plümäkers B, Reinert RR, Al-Lahham A, Lütticken R, Rink L.

Int J Med Microbiol. 2007 Oct;297(6):471-8. Epub 2007 May 3.

PMID:
17481952

Supplemental Content

Loading ...
Support Center